Drugs / CD40HVac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06007092 | Jul 2023 → Nov 2025 overdue | oropharyngeal carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD40HVac | “This study is a multicentric double-blind placebo-controlled dose escalation trial of a CD40HVac vaccine (humanized anti-CD40 mAb fused to HPV16 E6/E7 oncoproteins) adjuvanted...” NCT06007092 ↗ |
| Modality | Vaccine | “CD40HVac vaccine” NCT06007092 ↗ |
| Route | Subcutaneous | “The patients will receive three subcutaneous injections of a poly-ICLC- adjuvanted CD40HVac or placebo:” NCT06007092 ↗ |